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Introduction {#sec1}
============

Immune homeostasis at the site of inflammation is maintained primarily by peripherally induced FOXP3^+^ regulatory T (Treg) cells that develop from CD4^+^ T cells in the presence of interleukin (IL)-2 and transforming growth factor (TGF)-β ([@bib61]). These cells can also be induced *in vitro* when a naive CD4^+^ T cell is activated in the presence of IL-2, TGF-β, and retinoic acid (RA) ([@bib11], [@bib52]). *In vitro* induced Treg cells are called iTreg cells ([@bib1]). Identification and understanding the functions of factors important for the development of Treg cells are crucial for developing T cell-based therapies ([@bib6]). During the past decade, we have learned much about the mechanism of Treg cell development, particularly in mice. A network of transcription factors (TFs), including Foxp3, the Ikaros family of TFs, Nr4a nuclear receptors, c-Rel, Nfat, Smad factors, Stat5, and Runx factors, act in concert, leading to Treg differentiation ([@bib24]).

Although other TFs regulate Treg cell differentiation and function, FOXP3 is the key factor associated with iTreg cells. Deletion of FOXP3 results in severe autoimmunity in humans and mice ([@bib5], [@bib16]). Additionally, in mice, ectopic expression of Foxp3 confers suppressive ability to effector T cells ([@bib16]). Recent studies suggest that additional factors are involved in Treg lineage specification. For instance, analysis of co-expression networks of 24 cell types of the mouse immune system suggested that regulation of Foxp3-bound genes in Treg cells is independent of Foxp3 expression ([@bib56]). Also, ectopic expression of FOXP3 in effector T cells failed to induce the expression of most of Treg signature genes ([@bib21], [@bib51]). Moreover, disrupting *Foxp3* in mice does not revert Treg cells to conventional T cells ([@bib28]). In humans, T cell receptor (TCR) stimulation leads to transient expression of FOXP3 ([@bib2]) without any suppressive function. Furthermore, in rheumatoid arthritis patients, Treg cells show unaltered FOXP3 expression despite their severely compromised suppressive ability ([@bib37]). Thus, besides FOXP3, additional lineage-specific factors contribute to Treg cell suppressive function.

iTreg cells represent a reasonable model to study the factors contributing to the development of Treg cells, as these cells have properties of immune suppression *in vivo* and *in vitro* ([@bib13], [@bib23], [@bib31], [@bib22]). Besides expressing high Foxp3, both polyclonal and antigen-specific iTreg cells suppress effector cell response in mouse models ([@bib13], [@bib23]). However, although human iTreg cells are suppressive *in vitro*, their regulatory effects *in vivo* have been controversial. iTreg cells induced by TGF-β and IL-2 were not suppressive, whereas those generated with additional factors, namely RA ([@bib31]) and rapamycin ([@bib22]), were suppressive in xenogenic graft versus host disease (GVHD). Although the *in vivo* suppressive ability of RA-induced iTreg cells has also been questioned ([@bib46], [@bib49]), there is continued interest in understanding the mechanisms of iTreg development because of their great potential in clinical applications ([@bib26]). Furthermore, the conserved noncoding sequence 1 (CNS1) region on the FOXP3 locus serves as response element for TGF-β-SMAD signaling pathway and is required for the generation of peripheral Treg cells ([@bib54]). The CNS1 region also harbors RA response element ([@bib60]), suggesting that RA signaling may potentiate efficient Treg generation in the periphery, especially in the intestine, in which stromal cells and CD103^+^ dendritic cells (DCs) within mesenteric lymph node (mLN) and intestine express high levels of RA synthesizing the enzyme retinaldehyde dehydrogenase (RALDH2) ([@bib17]). Therefore, studying RA-induced iTreg cells may be functionally very relevant for intestinal Treg cells. In the present study, we comprehensively analyzed the transcriptomes of RA-induced iTreg cells across ten time points of development and identified hypermethylated in cancer 1 (HIC1; also called ZBTB29) as a TF specifically upregulated during iTreg cell differentiation. Here, we report the role of HIC1 in iTreg cell development and function.

Results {#sec2}
=======

RNA Sequencing Analysis Identifies Gene Expression Signature of iTreg Cell Priming {#sec2.1}
----------------------------------------------------------------------------------

To determine how naive T cells acquire a regulatory phenotype, we performed a kinetic analysis of the transcriptome of developing iTreg cells. RNA samples for sequencing were collected across ten time points during differentiation ([Figure S1](#mmc1){ref-type="supplementary-material"}A). About 90% of the iTreg cells were positive for FOXP3 ([Figure S1](#mmc1){ref-type="supplementary-material"}B) and could suppress the proliferation of responder cells ([Figure S1](#mmc1){ref-type="supplementary-material"}C).

In total, 2,927 genes were differentially expressed (DE) at one or more time points during iTreg cell development ([Table S1](#mmc2){ref-type="supplementary-material"}). Eighty percent of the DE genes were protein coding ([Figure 1](#fig1){ref-type="fig"}A). Transcriptional regulators were among the most common functional classes within the DE genes, second only to enzymes ([Figure 1](#fig1){ref-type="fig"}B). Although a few genes were already DE before 2 hr post-cell activation, most of the changes in gene expression were observed from 6 hr after induction of differentiation ([Figure 1](#fig1){ref-type="fig"}C). Unlike protein-coding genes, noncoding genes were predominantly downregulated early on, up to 24 hr ([Figure 1](#fig1){ref-type="fig"}C). As expected, several factors involved in Treg cell lineage specification (e.g., FOXP3, IKZF4, NR4A nuclear receptors, REL, NFAT, SMAD factors, and RUNX1) were DE in iTreg cells ([Figure 1](#fig1){ref-type="fig"}D; [Table S1](#mmc2){ref-type="supplementary-material"}) ([@bib32], [@bib39], [@bib57], [@bib59]). Pathway analysis of DE genes suggested that although at early time points (2--24 hr), signaling through cytokine-cytokine receptors, including TGF-β signaling and RAR/RXR signaling, was primarily enriched, at later time points, especially at 48 hr, several metabolism-related pathways, including cholesterol biosynthesis and glucose metabolism, were enriched ([Figure S1](#mmc1){ref-type="supplementary-material"}D; [Table S1](#mmc2){ref-type="supplementary-material"}).Figure 1RNA-Seq Analysis Identifies Gene Expression Signature of iTreg Cells(A) Pie chart showing the distribution of different RNA species among the genes differentially expressed (DE) during iTreg differentiation.(B) Figure showing the functional annotations of DE genes. The annotations were obtained from Ingenuity Pathway Analysis (IPA).(C) Bar chart showing the number of DE genes at respective time point (hours) for protein-coding (top) and noncoding (bottom) transcripts. Light green denotes genes upregulated in iTreg cells at the given time point for the first time in the time course, whereas dark green shows number of genes that were upregulated at already earlier time points. Similarly, light blue shows genes downregulated in iTreg cells for the first time, whereas dark blues shows genes downregulated at earlier time points.(D) Heatmap showing the expression of the top 50 DE genes across the time points of differentiation (0.5--72 hr). The first nine columns show the log~2~ fold change (FC) (iTreg/Th17), while the last nine columns show the expression (reads per kilobase of transcript per million mapped reads \[RPKM\]) of those genes in iTreg cells at different time points.(E) Heatmap of the log~2~ fold change of TFs that were DE in both iTreg cell (left) and Th17 cell differentiation (right). The time points are indicated at the bottom.(F) Expression profile (mean ± SE) of HIC1 expression (RNA-seq) in Th0, Th1, Th2, Th17, and iTreg cells differentiated from cord blood are shown as a line plot. TPM, transcript per million.

iTreg cells were metabolically similar to *ex vivo* Treg cells: several glycolytic enzymes (e.g., PGK1, PGAM1, ENO2, ENO3, ALDOC) were upregulated in iTreg cells ([Table S1](#mmc2){ref-type="supplementary-material"}) ([@bib44]). Moreover, unlike Th0 cells, iTreg cells used fatty acid oxidation (FAO) as a parallel source of energy, as suggested by upregulation of several enzymes of FAO (e.g., ACAA2, ACADVL, ACSL1, ACSL4, EC12, GPD2) in iTreg cells. Conversely, enzymes catalyzing the synthesis of fatty acid (e.g., FASN, ACAT2) or ACOT2, which catalyze the hydrolysis of acyl-CoAs to the free fatty acid and coenzyme A, were downregulated in iTreg cells.

We overlapped genes DE during iTreg cell priming in this study with the findings of DE genes from three other studies on Treg cells. First, compared with a recent human study ([@bib15]) analyzing CD4^+^ CD25^hi^ CD127^lo^ Treg and conventional T cells, 126 of 359 Treg-specific upregulated genes (e.g., FOXP3, IL2R, IKZF4, CTLA4, DUSP4) were DE in our data ([Table S1](#mmc2){ref-type="supplementary-material"}). Similarly, compared with mouse Treg signature genes ([@bib21]), 139 of 411 human orthologs of 603 mouse genes were DE in our data ([Table S1](#mmc2){ref-type="supplementary-material"}). Finally, compared with a study in which the authors analyzed Treg cell-specific FOXP3-dependent and FOXP3-independent genes ([@bib51]), 104 of 287 Treg-related genes were DE in our data ([Table S1](#mmc2){ref-type="supplementary-material"}). In conclusion, besides confirming a number of key genes previously associated with Treg cells, using the time-series design, we identified hundreds of genes DE during human iTreg cell priming that were not previously associated with Treg cell differentiation or function.

Genome-wide association studies (GWAS) have identified many risk loci associated with autoimmune diseases and various cancers. Autoimmune-disease-associated SNPs can be found near or over the TF binding site on the noncoding regions of the genome and modulate TF binding or epigenetic state ([@bib14]). We determined if disease-associated SNPs extracted from the National Human Genome Research Institute (NHGRI) GWAS catalog ([@bib58]) are enriched in genomic locations near (±100 kb) iTreg DE genes. Interestingly, the top diseases whose SNPs were enriched (adjusted p value \< 0.1) include several autoimmune diseases (e.g., inflammatory bowel disease \[IBD\], celiac disease \[CeD\], Crohn's disease \[CrD\], and rheumatoid arthritis \[RhA\]) ([Figure S1](#mmc1){ref-type="supplementary-material"}E). The analysis suggests that the SNPs may cause aberrant expression of iTreg signature genes in population that in turn may lead to autoimmune pathologies.

To identify potential TFs required for the development and function of iTreg cells, we studied the expression of all the TFs during iTreg development. To identify iTreg-specific factors, we compared the iTreg RNA sequencing (RNA-seq) data with our recently published human Th17 data ([@bib55]). Seventy-eight TFs were DE in both iTreg cells (compared with Th0) as well as Th17 cells (compared with Th0), and 149 and 84 TFs were DE only in the iTreg or Th17 cell subsets, respectively ([Figure 1](#fig1){ref-type="fig"}E; [Table S2](#mmc3){ref-type="supplementary-material"}). SMAD factors, NFAT factors, and EGR1 were among the TFs upregulated only in iTreg cells, whereas IRF factors, STAT3, STAT2, FOXO1, NOTCH1, and EGR2 were upregulated only in Th17 cells ([Table S2](#mmc3){ref-type="supplementary-material"}). Many known iTreg cell-related genes (e.g., *FOXP3*, *IKZF3*, *IKZF4*, *RUNX1*, *FOSL1*, *FOSL2)* were also upregulated in Th17 cells, albeit to lower levels or transiently and, therefore, were not in iTreg-specific TFs. Of 78 common factors, the majority behaved similarly (i.e., were either up or down in both subsets) ([Figure 1](#fig1){ref-type="fig"}E). However, there was a set of 9 TFs (i.e., HIC1, GFI1, PDLIM1, STAT4, NFKBID, EPAS1, ZBTB32, NR4A1, and NR4A2) that were upregulated in iTreg cells but downregulated in Th17 cells ([Figure 1](#fig1){ref-type="fig"}E; [Table S2](#mmc3){ref-type="supplementary-material"}). HIC1 had the opposite expression profile in the two subsets across all time points. Interestingly, SIRT1, a gene negatively regulated by HIC1 ([@bib8]), was among the 10 TFs (i.e., MAF, RB1, KLF11, TAF4B, BATF3, ARID5B, SIRT1, AHR, SMARCA2, and KLF4) upregulated in Th17 cells but downregulated in iTreg cells ([Table S2](#mmc3){ref-type="supplementary-material"}). Furthermore, HIC1 was uniquely upregulated only in iTreg cells, though it had expression similar to Th0 in all Th cell subsets, including Th1/2 (unpublished data) ([Figure 1](#fig1){ref-type="fig"}F).

To understand the development of transcriptome during iTreg cell differentiation, we investigated the transcription factor binding sites (TFBS) on the promoter of DE genes at each time point. On the promoter of upregulated genes, EGR1/2, the Ikaros family of TFs, and RA receptors were enriched at multiple time points across differentiation ([Figure S2](#mmc1){ref-type="supplementary-material"}A; [Table S2](#mmc3){ref-type="supplementary-material"}). FOXP3, beta-catenin, and ARID3A/B sites were enriched specifically on the promoters of downregulated genes. Notably, FOXP3 binding sites were enriched only at 24 and 48 hr ([Figure S2](#mmc1){ref-type="supplementary-material"}A), indicating that FOXP3 is not among the earliest regulators of iTreg differentiation. The binding of FOXP3 on the promoters of downregulated genes is consistent with its role as a transcriptional repressor ([@bib3]). Surprisingly, HIC1 was among the TFs whose binding sites were enriched already at 0.5 hr, along with TCR-induced TFs, including RelA-p65. Furthermore, HIC1 binding sites were enriched primarily on the promoters of upregulated genes, suggesting that in iTreg cells, HIC1 acts as a transcriptional activator besides its known role as a repressor ([@bib43]).

HIC1 Is Induced by RA, and It Contributes to the Suppressive Activity of iTreg Cells {#sec2.2}
------------------------------------------------------------------------------------

HIC1 was clearly upregulated at the protein level in iTreg cells, compared with Th0 cells. Importantly, HIC1 protein was detected as early as 12 hr, which preceded FOXP3 expression in iTreg cells ([Figure 2](#fig2){ref-type="fig"}A), suggesting that HIC1 is required early on in iTreg cell development program. To determine which differentiation factors induce HIC1 expression during early iTreg cell differentiation, we activated naive cells in the presence of different combinations of factors used for T helper (Th) and iTreg cell differentiation. Interestingly, all combinations containing RA resulted in upregulation of HIC1 expression ([Figure S2](#mmc1){ref-type="supplementary-material"}B), indicating that HIC1 in iTreg cells is induced by RA. Furthermore, we observed a dose-dependent increase in HIC1 expression with increasing concentration of RA, confirming that RA induces HIC1 expression in iTreg cells ([Figure 2](#fig2){ref-type="fig"}B). HIC1 was similarly upregulated in human iTreg cell generated from peripheral blood ([Figure S2](#mmc1){ref-type="supplementary-material"}C) as well as in mouse iTreg cells differentiated from splenic CD4^+^CD62L^+^ naive cells ([Figure S2](#mmc1){ref-type="supplementary-material"}D).Figure 2HIC1 Is Induced by RA, and It Contributes to the Suppressive Activity of iTreg Cells(A) Cells were stimulated in Th0 or iTreg conditions for the indicated time points (hours), followed by HIC1 and FOXP3 measurement by WB. A representative blot from two biological replicates is shown.(B) Cells were activated in presence of indicated concentrations of RA for 24 hr followed by measurement of HIC1 expression by WB. A representative image as well as mean of three biological replicates are shown. Error bars represent SE.(C) Cells were nucleofected with three siRNAs against HIC1 (si1--3) and one non-targeting (NT), followed by a rest for 24 hr. Cells were then cultured for 72 hr in iTreg culture conditions, and HIC1 expression was measured by WB. A representative blot is shown at the bottom, and the bar chart shows the mean ± SE of four biological replicates. Significance was measured by two-tailed paired t test. ^∗^p \< 0.05, ^∗∗^p \< 0.01.(D) FOXP3 expression was measured in HIC1-sufficient (red) and HIC1-deficient (blue) cells after 72 hr of culturing in iTreg conditions. Gray color shows isotype control. The bar charts show percentage FOXP3-positive cells (left) and median fluorescence intensity (MFI) (right) of three biological replicates (mean ± SE).(E) Histogram plots showing the proliferation of responder cells at a responder/suppressor ratio of 1:0.5 after 72 hr of activation in absence (responder only) or presence of HIC1-sufficient (NT) or HIC1-deficient (siHIC1) iTreg cells. The number on the histogram plot shows the percentage of proliferating cells. The line plot shows the percentage of proliferating responder cells at different responder/suppressor ratios. The shaded area shows the minimum and maximum value of the three replicates. Significance was measured using two-tailed paired t test. ^∗^p \< 0.05.(F) Same as (E), except that the responder cells were cultured in the presence of activated T cells (Th0) instead of iTreg cells.

To study the function of HIC1 in iTreg cells, we silenced HIC1 with small interfering RNA (siRNA). Three previously published HIC1-specific siRNAs ([@bib29]) successfully knocked down HIC1 expression ([Figure 2](#fig2){ref-type="fig"}C). Because siRNA1 and siRNA3, overlapping different regions of the HIC1 sequence, were more efficient, we decided to use them as a pooled siRNA cocktail in the subsequent knockdown experiments. HIC1-deficient cells were normal in terms of both the percentage and extent of FOXP3 protein expression ([Figure 2](#fig2){ref-type="fig"}D). More important, however, the suppressive ability of these cells was severely reduced at all responder/suppressor ratios ([Figure 2](#fig2){ref-type="fig"}E). Conversely, silencing HIC1 had no effect on the suppressive ability of Th0 cells ([Figure 2](#fig2){ref-type="fig"}F). These findings suggested that HIC1 is an important contributor to the suppressive function of iTreg cells, and its role is independent of FOXP3.

To study if HIC1 is functionally relevant for Treg cells *in vivo*, we analyzed transcriptome data from published *in vivo* Treg cell studies from human and mouse. The expression of HIC1 in the CD4^+^ CD25^+^ Treg cells sorted from human peripheral blood was comparable with CD3^+^ CD4^+^ CD45RA^+^ CCR7^+^ CD27^+^ naive CD4^+^ T cells ([@bib35]) both in the adult and in the fetus ([Figure S2](#mmc1){ref-type="supplementary-material"}E: data plotted from GEO: [GSE25087](ncbi-geo:GSE25087){#intref0010}), suggesting that HIC1 is not upregulated in Treg cells in the blood. Because HIC1 is induced in response to RA, we postulated that HIC1 is induced in intestinal Treg cells, in which RA is available in the milieu. Analysis of data from a mouse study (GEO: [GSE41229](ncbi-geo:GSE41229){#intref0015}) revealed that Hic1 was indeed upregulated in the Treg cells from mLN but not in the Treg cells from spleen ([Figure S2](#mmc1){ref-type="supplementary-material"}F) ([@bib27]), suggesting a role for HIC1 in intestinal homeostasis.

HIC1 Deficiency Alters iTreg Cell Transcriptome and Prepares the Cells for Alternative Fates {#sec2.3}
--------------------------------------------------------------------------------------------

To elucidate the mechanism of HIC1 action in iTreg cells, we performed RNA-seq on HIC1-deficient iTreg cells in three biological replicates at 48 and 72 hr post-cell differentiation. HIC1 expression was reduced in knockdown samples ([Figure S3](#mmc1){ref-type="supplementary-material"}A). In total, 1,205 and 447 genes were DE at 48 and 72 hr, respectively (false discovery rate \[FDR\] \< 0.05), indicating that HIC1 is a major regulator of iTreg cell priming ([Table S3](#mmc4){ref-type="supplementary-material"}). The top DE genes (FDR \< 0.05, \|log~2~\[fold change (FC)\]\| \> 1) were similarly regulated at the two time points ([Figure 3](#fig3){ref-type="fig"}A). HIC1-deficient cells had altered expression of a variety of immune-related genes, including cytokines, cytokine receptors, and TFs ([Figures 3](#fig3){ref-type="fig"}B and 3C). Among the upregulated immune response-related genes at one or more times were seven *HLA* genes, cytokine/chemokine (*IL1B*, *CXCL8*, *CXCL9*, *CXCL10*), and their receptors (*CCR1*, *CCR2*, *CCR5*, *CXCR3*, and *CXCR6*) ([Table S3](#mmc4){ref-type="supplementary-material"}). Among the downregulated cytokine/chemokine and their receptors were several tumor necrosis factor (TNF) factors and their receptors, as well as *IL2* and *IFNG*. Among the TFs, *ETV7*, *CREB3L3*, *CIITA*, and *PDLIM1* were upregulated, and *TEAD4*, *IRF8*, *RORC*, *EGR2*, and *ETV4* were downregulated at both time points ([Figure 3](#fig3){ref-type="fig"}C; [Table S3](#mmc4){ref-type="supplementary-material"}). CIITA upregulation was consistent with the increased expression of many HLA genes in HIC1-deficient cells. CIITA is required for Th1/2 differentiation ([@bib41], [@bib42]), suggesting that increased expression of CIITA in HIC1-deficient iTreg cells may drive the cells to effector lineages. To further confirm this idea, we investigated TBET and GATA3 expression in HIC1-deficient iTreg cells. HIC1-deficient cells were cultured under iTreg cell condition for 3 days, and the expression of TBET and GATA3 was measured by western blotting (WB). Interestingly, both TBET and GATA3 were significantly upregulated ([Figures 3](#fig3){ref-type="fig"}D and [S3](#mmc1){ref-type="supplementary-material"}C), suggesting that HIC1 deficiency makes the cells poised to differentiate to alternative lineages. Because of increased TBET expression, we hypothesized that HIC1-deficient iTreg cells when reactivated would produce higher interferon (IFN)-γ levels. Indeed, IFN-γ expression was significantly upregulated when HIC1-deficient iTreg cells were reactivated ([Figures 3](#fig3){ref-type="fig"}E and [S3](#mmc1){ref-type="supplementary-material"}D). To investigate if there was a global loss of iTreg cell gene signature upon HIC1 silencing, we performed gene set enrichment analysis (GSEA). We defined the top (48 hr, FDR = 0.05, log~2~\[FC\] \> 2) genes upregulated in iTreg cell condition in our time-series data as "iTreg cell signature genes" (163 genes). We ranked genes DE upon HIC1 silencing at 48 hr using Signal2Noise metric ([Experimental Procedures](#sec4){ref-type="sec"}). We then asked if iTreg cell signature genes lie at the top or bottom of the ranked list. The majority of iTreg cell signature genes were more abundant in the control samples than in the HIC1-deficient samples ([Figure 3](#fig3){ref-type="fig"}F), indicating that iTreg cell signature genes were lost in HIC1-deficient cells.Figure 3HIC1 Deficiency Alters iTreg Cell Transcriptome and Positions the Cells for Alternative Fates(A--C) Heatmaps showing the expression of top genes DE (FDR \< 0.05, \|log~2~\[FC\]\| \> 1) upon HIC1 silencing. siHIC1 and NT columns show expression (RPKM) in HIC1-deficient and HIC1-sufficient conditions, respectively. FC columns show fold change (iTreg/Th0) of the expression: (A) top DE genes (FDR = 0.05, \|log~2~\[FC\]\| \> 1) that were common to the two time points; (B) cytokines and chemokines and their receptors at 48 and 72 hr; (C) TFs at 48 and 72 hr.(D) NT- or siHIC1-treated cells were cultured in iTreg condition for 3 days, followed by WB. Blots were quantitated in ImageJ (NIH). Normalization was done by GAPDH. Log~2~(FC) was calculated with respect to NT samples. Significance was determined using two-tailed paired t test. ^∗^p \< 0.05. Data from four biological replicates are shown.(E) Boxplot showing IFN-γ expression in NT- or siHIC1-treated iTreg cells when reactivated after 72 hr with PMA and ionomycin. Data from three biological replicates are shown. Significance was determined using two-tailed paired t test. ^∗^p \< 0.05.(F) iTreg signature genes were top upregulated genes (log~2~FC \> 2) in iTreg conditions compared with Th0 at 48 hr ([Table S1](#mmc2){ref-type="supplementary-material"}). Gene set enrichment analysis (GSEA) ([@bib50]) was then used to test where the genes from this set lie in the ranked HIC1 knockdown (KD) 48 hr data. Each vertical line in the plot shows one gene. Lines toward the red indicate genes that are enriched in NT sample, and those toward the blue indicate enrichment in siHIC1 samples.(G) Bar chart showing the NHGRI diseases and traits whose SNPs are enriched around (±100 kb) genes DE upon HIC1 silencing. All the diseases are enriched at an FDR of 0.05, and those that cross the dotted line are enriched at an FDR of 0.01.

We studied disease-associated SNPs near (±100 kb) genes DE upon HIC1 silencing. Almost all the autoimmune diseases that were enriched around iTreg DE genes were also enriched in genes DE upon HIC1 silencing ([Figure 3](#fig3){ref-type="fig"}G). The analysis suggests that HIC1 indeed regulates the expression of a significant fraction of immune related genes in iTreg cells.

Although FOXP3 protein expression was unaffected by HIC1 silencing ([Figure 2](#fig2){ref-type="fig"}D), FOXP3 mRNA was slightly upregulated at 72 hr ([Table S3](#mmc4){ref-type="supplementary-material"}). Furthermore, HIC1 silencing did not alter the expression of different FOXP3 isoforms ([Figure S3](#mmc1){ref-type="supplementary-material"}E). Pathway analysis of genes DE upon HIC1 silencing suggested that many signaling pathways, particularly VDR/RXR activation as well as Nur77 signaling pathways, are perturbed in HIC1-deficient cells ([Figure S3](#mmc1){ref-type="supplementary-material"}F). TFBS enrichment analysis on the promoters of DE genes in HIC1-deficient cells suggested that many of the TFBS that were enriched on the promoters of upregulated iTreg genes ([Figure S2](#mmc1){ref-type="supplementary-material"}A) were also enriched on the promoters of genes downregulated upon HIC1 silencing ([Figure S3](#mmc1){ref-type="supplementary-material"}G; [Table S3](#mmc4){ref-type="supplementary-material"}). This category of TFs includes EGR1, EGR3, HIF1A, Ikaros, AHR, and REST. Taken together, the transcriptome of HIC1-deficient iTreg cells suggests that HIC1 deficiency alters the transcriptome of iTreg cells and prepares the cells for effector-like functions.

Chromatin Immunoprecipitation Sequencing Analysis Identifies Genome-wide Binding Sites of HIC1 during iTreg Cell Differentiation {#sec2.4}
--------------------------------------------------------------------------------------------------------------------------------

Fractionation studies showed that HIC1 translocated to the nucleus during iTreg differentiation at both the 72 and 120 hr time points ([Figure 4](#fig4){ref-type="fig"}A). This was further validated by fluorescent microscopy, with which we found HIC1 translocation already at 24 hr ([Figure S4](#mmc1){ref-type="supplementary-material"}A). We performed chromatin immunoprecipitation sequencing (ChIP-seq) analysis in iTreg cells (72 hr). Library complexity analysis revealed that the ChIP-seq libraries had 15 million to 20 million unique reads ([Figure S4](#mmc1){ref-type="supplementary-material"}B). ChIP-seq analysis identified 16,424 and 31,604 HIC1 binding peaks in the two replicates, with 6,628 peaks common between the two replicates (irreproducibility discovery rate \[IDR\] analysis \[[@bib30]\], q \< 0.1; [Table S4](#mmc5){ref-type="supplementary-material"}). Approximately two thirds of HIC1 binding sites were located in intronic and distal intergenic regions, suggesting that HIC1 potentially regulates the expression of genes by binding to these distal regulatory elements ([Figure 4](#fig4){ref-type="fig"}B). About 18% of the binding sites were located at 5ʹUTR, the transcription start site (TSS), and promoter regions ([Figure 4](#fig4){ref-type="fig"}B). Further analysis of distance between peaks and nearest TSS revealed that 49% of the HIC1 peaks were found within 10 kb up- or downstream of the nearest TSS ([Figure 4](#fig4){ref-type="fig"}C), indicating that HIC1 is likely recruited to these regions in iTreg cells to directly regulate the transcriptional activity of the neighboring genes. Moreover, *de novo* TF motif analysis at HIC1 peaks revealed binding sites for several TFs, with motifs for AP1, ETS1, HIC1, RUNX1, and NFKB2 being the top five ([Figure 4](#fig4){ref-type="fig"}D; [Table S4](#mmc5){ref-type="supplementary-material"}).Figure 4ChIP-Seq Analysis Identifies Genome-wide Binding Sites of HIC1 during iTreg Cell Differentiation(A) Blots showing HIC1 localization from fractionation experiments (representative of three replicates) with Th0 and iTreg cells at the indicated times. ⍺-Tubulin and LSD1 were used as loading controls for cytoplasmic and nuclear fractions, respectively.(B) Pie chart showing the genomic distribution of HIC1 peaks at 72 hr of iTreg polarization detected using MACS on ChIP-seq data.(C) Histogram plot showing the distribution of HIC1 peaks around transcriptional start sites.(D) Top five motifs detected in *de novo* motif discovery using the Homer tool. Motif discovery was done on peaks with IDRs \< 0.1.(E) Venn diagram showing the overlap of HIC1 binding sites from ChIP-seq experiments and genes that are DE upon HIC1 silencing. The associated bar chart shows the direction of differential expression of overlapped genes (direct targets). TFs among the direct targets are also plotted separately.(F) Heatmap showing the expression of HIC1 direct targets upon HIC1 silencing: the top (logFC \< --1 or \> 1) DE genes (left) as well as TFs (right).(G) University of California, Santa Cruz (UCSC), Genome Browser shots for the key genes that are upregulated (top) or downregulated (bottom) upon HIC1 silencing.(H) Pathway analysis of direct targets genes. Analysis was done using Ingenuity Pathway Analysis (IPA).

To identify direct and indirect targets of HIC1, ChIP-seq results were overlapped with the RNA-seq of HIC1-deficient iTreg cells at 48 and 72 hr ([Table S3](#mmc4){ref-type="supplementary-material"}). Altogether, 449 genes were directly regulated (had a neighboring HIC1 binding peaks and were DE upon HIC1 silencing) by HIC1, with 57 and 299 genes regulated specifically at 48 and 72 hr, respectively, and 93 genes at both time points ([Figure 4](#fig4){ref-type="fig"}E, left; [Table S4](#mmc5){ref-type="supplementary-material"}). Functional annotation of HIC1 direct targets suggested that they include transcriptional regulators as well as kinases and phosphatases ([Figures S4](#mmc1){ref-type="supplementary-material"}C and S4D). On the basis of enrichment of HIC1 binding sites on the promoters of iTreg DE genes ([Figure S2](#mmc1){ref-type="supplementary-material"}A), we predicted that HIC1 would bind to both up- and downregulated genes. Indeed, HIC1 was bound near the promoters of both up- and downregulated genes in iTreg cells ([Figure 4](#fig4){ref-type="fig"}E, right; [Table S3](#mmc4){ref-type="supplementary-material"}). HIC1 directly bound and positively regulated the expression of several important Treg cell-associated genes, including *DUSP2*, *DUSP5*, *TIGIT*, and *CTLA4*. Interestingly, HIC1 also bound and negatively regulated genes involved in effector T cell functions, such as *CCR2*, *CCR5*, *CXCR3*, and *CXCR6* ([Figures 4](#fig4){ref-type="fig"}F and 4G).

To study the connectivity of HIC1 to its direct and indirect target TFs ([Figures S5](#mmc1){ref-type="supplementary-material"}A and S5B), we constructed a HIC1-TF interaction network ([Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}). The TFs were highly connected and formed an integrated network ([Figure S5](#mmc1){ref-type="supplementary-material"}C). TFs that positively regulate Treg cell differentiation and function, including ID2, SMAD3, NR4A, and EGR family TFs, CREM, REL and IRF8, were among the highly connected nodes in the network and may form positive regulatory module. Conversely, TFs CIITA, E2F1, and JUN may form a negative regulatory module during iTreg cell differentiation. Several Th cells related to signaling pathways, including TCR signaling, Th1/Th2 pathways, NF-kB signaling, CXCR4 signaling, and STAT3 signaling, were enriched among HIC1 direct target genes ([Figure 4](#fig4){ref-type="fig"}H). Altogether, these findings strongly indicate that HIC1 uses both positive and negative gene regulatory modules to program iTreg cell differentiation.

SNPs Associated with Autoimmune Diseases Overlap with HIC1 Binding Sites and Alter HIC1 DNA Binding Ability {#sec2.5}
-----------------------------------------------------------------------------------------------------------

A SNP at the HIC1 motif could result in a gain or loss of HIC1 binding that may alter the target gene expression and contribute to disease. Therefore, we examined autoimmune-associated SNPs that specifically fall within the HIC1 peak ([Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}). Interestingly, SNPs associated with 6 of 11 autoimmune diseases tested were enriched within the peak regions with maximum number of SNPs found for CrD followed by RhA and ulcerative colitis (UC) ([Figure 5](#fig5){ref-type="fig"}A). The analysis suggested that HIC1 ChIP-seq peaks did harbor SNPs that are relevant in autoimmune disease. To take it to the next level, we asked if autoimmune-disease-associated SNPs fall exactly within the HIC1 motif. Three proxy SNPs in linkage disequilibrium (LD) with four lead SNPs overlapped with HIC1 motif within the peak regions ([Figure 5](#fig5){ref-type="fig"}B) potentially disrupting the binding of HIC1 to the target sites. Of the three SNPs, one each fell into promoter (PLAU), intronic (IRF5), and intergenic (TRAF1) regions ([Figure 5](#fig5){ref-type="fig"}B). Interestingly, PLAU (plasminogen activator, urokinase) was identified as a key Treg gene that regulated FOXP3 expression and was required for suppressive activity ([@bib20]).Figure 5SNPs Associated with Autoimmune Diseases Overlap with HIC1 Binding Sites and Alter the HIC1 DNA Binding Ability(A) Enrichment of autoimmune-associated SNPs at HIC1 binding sites compared with a random set of background SNPs.(B) SNPs overlapping the HIC1 motif ([Experimental Procedures](#mmc1){ref-type="supplementary-material"}). rsID, overlapping SNP ID; proxyTo, lead SNP to which overlapping SNP is a proxy; Chr, chromosome; location, SNP location; major, major allele; minor, minor allele; disease, disease to which lead SNP is attributed; motif, motif sequence (SNPs in red); motifStart, location of motif start; motifStrand, strand info.(C) Two DNA sequences with HIC1 binding site (HIC1 wild-type \[WT\]) and corresponding negative control DNA sequences in which the HIC1 motif has been mutated (HIC1 MT) were used as controls ([Table S5](#mmc6){ref-type="supplementary-material"}). Data shown here are a representative of three biological replicates. Significance was determined with one-tailed paired t test. ^∗^p \< 0.05.

To confirm whether these SNPs could change HIC1 binding, we performed DNA affinity precipitation assays (DAPAs). HIC1 was bound to oligonucleotides with reference genome as bait sequence; however, the binding was reduced in all the oligonucleotides with mutations corresponding to disease-associated SNPs ([Figure 5](#fig5){ref-type="fig"}C). Thus, we conclude that disease-associated SNPs alter HIC1 binding to DNA *in vitro*. These findings suggest a potential mechanism for how a disease-associated genetic variant modulates HIC1-mediated gene regulation and affects the expression of its target gene.

Discussion {#sec3}
==========

HIC1 is a member of the POK/ZBTB protein family that includes several TFs. HIC1 has been extensively studied in the context of cancer. It acts as a tumor suppressor, and it is involved in several major processes of carcinogenesis, including cell growth and survival and cell migration ([@bib45]). HIC1 is probably most relevant for the function of intestinal Treg cells, as the Treg cells from blood had HIC1 level comparable with that of naive cells. A recent *in vivo* study showed that HIC1 expression indeed was restricted to intestinal immune cells. HIC1 deletion did not affect FOXP3 expression in CD4^+^ T cells, but it was required for intestinal homeostasis, as T cell specific deletion of HIC1 led to increased Th17 bias in lamina propria and mLN ([@bib7]). Our findings, along with these studies, suggest that HIC1 may play an important role in intestinal homeostasis by maintaining Treg cell suppressive ability to sustain tolerance to innocuous antigens.

NR4A receptors were among the TFs that, like HIC1, were upregulated in iTreg cells but downregulated in Th17 cells. NR4A1-3 receptors are required for the thymic Treg cell developmental program via directly binding to the promoter of *Foxp3* ([@bib48]). Other potential TFs that may regulate the development and function of iTreg cells are PDLIM1, NFKBID, EPAS1, and ZBTB32, as they had profiles similar to HIC1. PDLIM1 and NFKBID are particularly interesting, as they regulate NF-κB signaling by sequestering p65 subunit in cytoplasm (PDLIM1) ([@bib40]) or by inhibiting NF-κB in the nucleus by acting as atypical IκB (NFKBID) ([@bib47]). EPAS1 is a direct STAT6 target and it regulated STAT6-mediated RUNX1 expression by direct binding to RUNX1 promoter ([@bib38]). ZBTB32, which is another member of HIC1 family, controls the proliferative burst of natural killer (NK) cells in response to infection ([@bib4]).

A recent study reported a RARE element conserved between mouse and human on the promoter of HIC1 ([@bib18]). Moreover, we analyzed the HIC1 flanking regions for TFBS using MATCH tool in TRANSFAC and found a few RARE elements within an intron of the SMG6 gene downstream of HIC1. [@bib18] found that the RARE sites on the promoter and downstream interact to enhance the transcription of HIC1. These data suggest that RA directly regulates HIC1 expression by directly binding to RARE elements near HIC1.

Several mechanisms may explain the lack of suppressive ability in HIC1-deficient iTreg cells. HIC1 silencing led to upregulation of several TFs, including CIITA, TBET, GATA3, BATF, and MAF, which support effector T cell differentiation. ChIP-seq data show that HIC1 directly binds to the upstream of these TFs and, therefore, may directly suppress their expression in iTreg. Similar to B cells ([@bib63]), HIC1 repressed CIITA expression in iTreg cells ([Figure 3](#fig3){ref-type="fig"}C). Importantly, constitutive expression of CIITA in CD4 T cells leads to regulation and induction of Th2 cytokine production ([@bib42]) and expression of major histocompatibility complex (MHC) class II molecules. Consistent with increased CIITA expression, several HLA genes were also upregulated upon HIC1 deficiency ([Figure 3](#fig3){ref-type="fig"}B). Thus, in line with these findings, our results suggest that increased HIC1 expression in iTreg cells may limit the Th1/2 inflammatory response by keeping CIITA expression low.

HIC1 may also regulate the suppressive ability of iTreg cells through RORC. RORC-expressing Treg cells have enhanced suppressive capacity in intestinal inflammation ([@bib62]). RA in the intestinal microenvironment may facilitate the induction of RORC. In germ-free mice in which the intestinal microbiota is compromised, both Treg cell numbers and their efficacy decline as exhibited by reduced expression of CTLA4, ICOS, and IL10 ([@bib53]). Interestingly, in our data, CTLA4 expression was reduced upon HIC1 silencing both at 48 and 72 hr ([Figure S3](#mmc1){ref-type="supplementary-material"}B). We show that RORC is a direct target of HIC1, as the latter binds to RORC promoter during iTreg cell development, and RORC was downregulated in HIC1-silenced cells at both times ([Figures 3](#fig3){ref-type="fig"}A and 3C), suggesting that HIC1 is a positive regulator of RORC.

Several glycolytic enzymes, including glucokinase (GCK), the enzyme required for the first step of glycolysis, were significantly downregulated in HIC1-deficient cells ([Table S3](#mmc4){ref-type="supplementary-material"}), suggesting that these cells lost the "iTreg type" metabolic profile given that Treg cells preferentially use glycolysis as a source of energy ([@bib33]).

To date, only a dozen HIC1 direct target genes have been identified ([@bib45]). We found that HIC1 was bound in the vicinity of several genes, including CTLA4, PD1, TIGIT, EBI3, EGR2/3, NR4A receptors, ID2/3, and IRF8, that contribute to Treg cell function ([@bib10], [@bib12], [@bib25], [@bib34], [@bib36], [@bib48]). The analysis of SNPs within the HIC1 motif identified PLAU as a candidate that can have perturbed expression because of altered HIC1 binding to its promoter. PLAU was not DE in iTreg cells, but its receptor PLAUR was upregulated in iTreg cells at 72 hr compared with Th0. Further studies are required to understand the regulation of PLAU expression by HIC1 and the role of the SNP. Together, our results identify HIC1 as a crucial factor regulating iTreg development and function. Mechanistically, HIC1 binds to the promoters of TFs required for Th1/2/17 cell development and represses their transcription in iTreg cells.

Experimental Procedures {#sec4}
=======================

CD4^+^ Cell Isolation and Differentiation to iTreg Cells {#sec4.1}
--------------------------------------------------------

CD4^+^ T cells were isolated from human umbilical cord blood as described previously ([@bib19]). CD25 depletion was performed using LD columns and a CD25 depletion kit (Miltenyi Biotec). CD4^+^CD25^−^ cells from multiple donors (three or more) were activated directly or pooled before activation with plate-bound anti-CD3 (500 ng/24-well culture plate well; Immunotech) and soluble anti-CD28 (500 ng/mL; Immunotech) at a density of 2 × 10^6^ cells/mL of X-vivo 15 serum-free medium (Lonza). For iTreg differentiation, the medium was supplemented with IL-2 (12 ng/mL), TGF-β (10 ng/mL) (both from R&D Systems), all-trans retinoic acid (ATRA) (10 nM; Sigma-Aldrich), and human serum (10%) and cultured at 37°C in 5% CO~2~. Control Th0 cells were stimulated with plate-bound anti-CD3 soluble anti-CD28 X-vivo 15 serum-free medium without cytokines.

Suppression Assays {#sec4.2}
------------------

To evaluate the ability of a candidate population to suppress the proliferation of an effector population (responder cells), we used a mixed lymphocyte reaction (MLR). Responder cells (Tres) were CD4^+^CD25^−^ cells isolated from a peripheral blood buffy coat with the Dynal CD4^+^ Isolation Kit (Invitrogen) and CD25 depletion kit (Miltenyi Biotec). To reduce the variability between different responder cell populations, a set of responder cells were isolated and stored at --80°C in freezing medium (90% fetal calf serum \[FCS\] and 10% DMSO). On day 1 of the assay, responder cells were labeled with cell trace violet (EF670/CTV; Thermo Fisher Scientific). Fifty thousand responder cells were cultured in different wells in the presence of Th0 or iTreg cells in ratios of 1:1, 1:0.5, 1:0.25, 1:0.125, and 1:0. The division of responder cells was analyzed by dye dilution at the end of the assay (day 4). Suppression was calculated at 1:0.25 or 1:5 ratios. The percentage suppression was calculated using the following formula: % suppression = \[% of dividing cells (Tres-iTreg)/% of dividing cells in Tres\] × 100.

siRNA-Mediated Gene Knockdown {#sec4.3}
-----------------------------

Four million cells were transfected with 300 pmol of siRNA in 100 μl of OptiMEM media using Amaxa nucleofector device (Lonza). For details, see [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Intracellular Staining and Flow Cytometry {#sec4.4}
-----------------------------------------

Intracellular staining was performed using buffer sets of Human Regulatory T Cell Staining Kit (eBioscience/Thermo Fisher Scientific), following the manufacturer's protocol. For intracellular staining of IFN-γ, HIC1-deficient and HIC1-sufficient iTreg cells were first activated with phorbol myristate acetate (PMA) and ionomycin for 4 hr followed by treatment of brefeldin A for 90 min. The antibodies are listed in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

RNA Isolation, RNA-Seq Sample Preparation, and Data Analysis {#sec4.5}
------------------------------------------------------------

RNA was isolated using the RNeasy Mini Kit (QIAGEN). Libraries for RNA-seq were prepared using the Illumina TruSeq Stranded mRNA Sample Preparation Kit. The reads were aligned using tophat2, and counts were determined using HTSeq-count. DE calling was performed using edgeR. For details, please see [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Chromatin Immunoprecipitation Assay and ChIP-Seq {#sec4.6}
------------------------------------------------

ChIP assay was performed as described previously ([@bib19]). For details, see [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

DAPA {#sec4.7}
----

DAPA experiments were performed as described previously with minor modifications ([@bib19]). Details can be found in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Analysis of TFBS {#sec4.8}
----------------

Overrepresentation of TFBS on the promoters of DE genes was performed using the commercial version of an FMatch tool at the TRANSFAC database (Release 2017.2). For details, see [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Pathway Analysis {#sec4.9}
----------------

Pathway analysis was performed using Ingenuity Pathway Analysis (IPA) (<https://www.ingenuity.com>; May 2016). Both overrepresentation (positive *Z* score) and underrepresentation (negative *Z* score) were calculated. Benjamini-Hochberg corrected p values \< 0.05 was considered to indicate significance.

GSEA {#sec4.10}
----

GSEA was performed using the tool from the Broad Institute ([@bib50]). For details, see [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Statistical Methods {#sec4.11}
-------------------

For comparison of means, two-tailed paired t tests were performed, and p values \< 0.05 were considered to indicate significance unless otherwise stated. The Benjamini-Hochberg method was used for multiple hypothesis correction whenever applicable. The statistical methods used for SNP analysis enrichment analysis, pathways analysis, and other procedures are described the respective sections.

Ethical Approval {#sec4.12}
----------------

The use of the blood of unknown donors was approved by the Ethics Committee of the Hospital District of Southwest Finland (24.11.1998 article 323). Mouse studies were conducted according to the guidelines of Provincial Government of Southern Finland and handled in accordance with the institutional animal care policies of University of Turku (license KEK/2010-1512). Female wild-type mice aged 8--12 weeks of C57BL/6 background were used for the experiments in this study.

Data and Software Availability {#app1}
==============================

The accession numbers for the RNA-seq and ChIP-seq data reported in this paper are GEO: [GSE90570](ncbi-geo:GSE90570){#intref0025} and [GSE99889](ncbi-geo:GSE99889){#intref0030}, respectively.
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